$APVO
Aptevo Therapeutics Inc.

2020 Q2 Form 10-Q Financial Statement

#000156459020040295 Filed on August 14, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2 2019 Q1
Revenue $473.0K $7.360M $7.022M
YoY Change -93.57% 7.82% 72.49%
Cost Of Revenue $5.985M $3.847M
YoY Change 136.19% 116.0%
Gross Profit $1.375M $3.175M
YoY Change -67.96% 38.65%
Gross Profit Margin 18.68% 45.22%
Selling, General & Admin $2.840M $6.538M $7.330M
YoY Change -56.56% -6.91% -3.45%
% of Gross Profit 475.49% 230.87%
Research & Development $4.440M $7.733M $7.285M
YoY Change -42.58% -20.39% -11.15%
% of Gross Profit 562.4% 229.45%
Depreciation & Amortization $300.0K $580.0K $583.0K
YoY Change -48.28% -3.33% -0.68%
% of Gross Profit 42.18% 18.36%
Operating Expenses $7.280M $10.40M $11.16M
YoY Change -30.03% -37.83% -29.31%
Operating Profit -$6.807M -$12.90M -$11.44M
YoY Change -47.22% 3.63% -15.27%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $4.000K -$436.0K -$578.0K
YoY Change -100.92% -37.71% 63.74%
Pretax Income -$6.800M -$10.84M -$11.74M
YoY Change -37.27% -17.6% -15.23%
Income Tax
% Of Pretax Income
Net Earnings -$6.803M -$13.33M -$12.02M
YoY Change -48.96% 1.42% -13.25%
Net Earnings / Revenue -1438.27% -181.11% -171.15%
Basic Earnings Per Share
Diluted Earnings Per Share -$2.105M -$4.140M -$7.656M
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q2 2019 Q2 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.600M $21.00M $37.00M
YoY Change -63.81% -53.02% -40.03%
Cash & Equivalents $10.15M $20.96M $37.01M
Short-Term Investments
Other Short-Term Assets $2.600M $3.170M $10.50M
YoY Change -17.98% -74.44% 58.37%
Inventory $6.967M $4.300M
Prepaid Expenses $5.200M
Receivables $300.0K $7.378M $5.800M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $10.50M $43.67M $57.60M
YoY Change -75.96% -34.03% -25.39%
LONG-TERM ASSETS
Property, Plant & Equipment $6.600M $4.610M $4.978M
YoY Change 43.17% -17.68% -15.63%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $757.0K $1.248M $1.249M
YoY Change -39.34% -89.94% -88.85%
Total Long-Term Assets $8.009M $22.43M $23.20M
YoY Change -64.29% -5.76% 0.87%
TOTAL ASSETS
Total Short-Term Assets $10.50M $43.67M $57.60M
Total Long-Term Assets $8.009M $22.43M $23.20M
Total Assets $18.51M $66.10M $80.80M
YoY Change -72.0% -26.56% -19.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.662M $11.90M $11.04M
YoY Change -60.84% 25.31% 51.27%
Accrued Expenses $2.000M $3.600M $6.100M
YoY Change -44.44% 33.33% 190.48%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $7.000M $16.60M $18.30M
YoY Change -57.83% -8.3% 5.78%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $19.56M $19.40M
YoY Change -100.0% 27.0% 38.57%
Other Long-Term Liabilities $2.900M $13.00K $4.000M
YoY Change 22207.69% -97.4% 566.67%
Total Long-Term Liabilities $2.900M $19.57M $23.40M
YoY Change -85.18% 23.09% 60.27%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.000M $16.60M $18.30M
Total Long-Term Liabilities $2.900M $19.57M $23.40M
Total Liabilities $9.900M $39.93M $41.70M
YoY Change -75.21% 17.44% 31.13%
SHAREHOLDERS EQUITY
Retained Earnings -$152.8M
YoY Change
Common Stock $179.0M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $8.650M $26.20M $39.13M
YoY Change
Total Liabilities & Shareholders Equity $18.50M $66.13M $80.80M
YoY Change -72.02% -26.53% -19.36%

Cashflow Statement

Concept 2020 Q2 2019 Q2 2019 Q1
OPERATING ACTIVITIES
Net Income -$6.803M -$13.33M -$12.02M
YoY Change -48.96% 1.42% -13.25%
Depreciation, Depletion And Amortization $300.0K $580.0K $583.0K
YoY Change -48.28% -3.33% -0.68%
Cash From Operating Activities -$4.630M -$15.90M -$13.84M
YoY Change -70.88% -0.63% -18.46%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $153.0K
YoY Change -100.0% -67.65%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Investing Activities $0.00 $0.00 -$153.0K
YoY Change -100.0% -100.65%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 -110.0K 20.37M
YoY Change -100.0% -134.37% -3764.21%
NET CHANGE
Cash From Operating Activities -4.630M -15.90M -13.84M
Cash From Investing Activities 0.000 0.000 -153.0K
Cash From Financing Activities 0.000 -110.0K 20.37M
Net Change In Cash -4.630M -16.01M 6.376M
YoY Change -71.08% 373.67% 6.66%
FREE CASH FLOW
Cash From Operating Activities -$4.630M -$15.90M -$13.84M
Capital Expenditures $0.00 $153.0K
Free Cash Flow -$15.90M -$14.00M
YoY Change 0.0% -19.79%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Shell Company
EntityShellCompany
false
dei Document Transition Report
DocumentTransitionReport
false
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity File Number
EntityFileNumber
001-37746
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-1567056
dei Entity Address Address Line1
EntityAddressAddressLine1
2401 4th Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1050
dei Entity Address City Or Town
EntityAddressCityOrTown
Seattle
dei Entity Address State Or Province
EntityAddressStateOrProvince
WA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
98121
dei City Area Code
CityAreaCode
206
dei Local Phone Number
LocalPhoneNumber
838-0500
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3747000
CY2019Q4 apvo Assets Held For Sale Non Current
AssetsHeldForSaleNonCurrent
7465000
CY2020Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
757000
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
4662000
CY2020Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1419000
CY2019Q4 apvo Assets Held For Sale Current
AssetsHeldForSaleCurrent
16309000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
179653000
CY2020Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
693000
CY2020Q2 us-gaap Assets
Assets
18509000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3327000
CY2019Q4 us-gaap Liabilities
Liabilities
41566000
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
45000
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
us-gaap:RoyaltyMember
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-167856000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
11842000
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 apvo Liabilities Held For Sale Current
LiabilitiesHeldForSaleCurrent
8135000
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
944000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
38239000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
53408000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
7280000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
10404000
us-gaap Operating Expenses
OperatingExpenses
14902000
us-gaap Operating Expenses
OperatingExpenses
21566000
CY2020Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-2.10
CY2019Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-3.37
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-5.14
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-8.69
CY2019Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
-0.77
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
3.95
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
-1.07
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.10
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3232811
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
14338000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3234232
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3234232
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8807000
apvo Increase Decrease In Royalties Receivable
IncreaseDecreaseInRoyaltiesReceivable
288000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
39130000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
19946000
apvo Increase Decrease In Assets And Liabilities Held For Sale
IncreaseDecreaseInAssetsAndLiabilitiesHeldForSale
-1719000
apvo Increase Decrease In Sales And Rebates Discounts
IncreaseDecreaseInSalesAndRebatesDiscounts
351000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29735000
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
28120000
apvo Proceeds From Issuance Of Common Stock Warrants And Pre Funded Warrants Net
ProceedsFromIssuanceOfCommonStockWarrantsAndPreFundedWarrantsNet
20297000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-22104000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9792000
apvo Stock Issued During Period Value Common Stock Pre Funded Warrants And Warrants Net
StockIssuedDuringPeriodValueCommonStockPreFundedWarrantsAndWarrantsNet
20206000
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-58000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
995000
CY2020Q1 apvo Cash Payment Received
CashPaymentReceived
29250000
CY2020Q1 apvo Net Carrying Value Of Assets Transferred
NetCarryingValueOfAssetsTransferred
13376000
CY2020Q1 apvo Transaction Cost
TransactionCost
1880000
CY2020Q1 apvo Minimum Transition Services Agreement Tsa Fund
MinimumTransitionServicesAgreementTSAFund
406000
CY2020Q1 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
14338000
apvo Purchase Of Working Capital
PurchaseOfWorkingCapital
9500000
CY2020Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
we effected a 1-for-14 reverse stock split (the “Reverse Split”) of our common stock pursuant to which every 14 shares of our common stock issued and outstanding as of March 26, 2020 were automatically combined into one issued and outstanding share of common stock. No fractional shares were issued as a result of the reverse stock split.
CY2020Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.071
apvo Fractional Shares Reverse Stock Split
FractionalSharesReverseStockSplit
0
apvo Royalty Rate
RoyaltyRate
0.025
CY2020Q1 us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
30000000
CY2020Q1 us-gaap Escrow Deposit
EscrowDeposit
750000
CY2020Q1 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
22100000
CY2020Q1 us-gaap Line Of Credit Facility Annual Principal Payment
LineOfCreditFacilityAnnualPrincipalPayment
20000000
CY2020Q1 apvo Facility Fee
FacilityFee
2100000
CY2020Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2100000
apvo Net Working Capital Sold
NetWorkingCapitalSold
9100000
apvo Working Capital Is Due
WorkingCapitalIsDue
100000
CY2019Q4 us-gaap Disposal Group Including Discontinued Operation Accounts Notes And Loans Receivable Net
DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet
7022000
CY2019Q4 us-gaap Disposal Group Including Discontinued Operation Inventory Current
DisposalGroupIncludingDiscontinuedOperationInventoryCurrent
6140000
CY2019Q4 us-gaap Disposal Group Including Discontinued Operation Prepaid And Other Assets Current
DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent
3147000
CY2019Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
16309000
CY2019Q4 us-gaap Disposal Group Including Discontinued Operation Intangible Assets Noncurrent
DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent
4420000
CY2019Q4 apvo Disposal Group Including Discontinued Operation Vat Receivable And Deposit
DisposalGroupIncludingDiscontinuedOperationVATReceivableAndDeposit
3045000
CY2019Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation
AssetsOfDisposalGroupIncludingDiscontinuedOperation
23774000
CY2019Q4 us-gaap Disposal Group Including Discontinued Operation Accounts Payable And Accrued Liabilities Current
DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent
5043000
CY2019Q4 apvo Disposal Group Including Discontinued Operation Royalties Payable
DisposalGroupIncludingDiscontinuedOperationRoyaltiesPayable
2018000
CY2019Q4 apvo Disposal Group Including Discontinued Operation Accrued Payroll Payable
DisposalGroupIncludingDiscontinuedOperationAccruedPayrollPayable
654000
CY2019Q4 us-gaap Disposal Group Including Discontinued Operation Other Current Liabilities
DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities
420000
CY2019Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
8135000
CY2019Q2 us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
2492000
us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
1580000
us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
2769000
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
14338000
apvo Disposal Group Including Discontinued Operations Deferred Revenue
DisposalGroupIncludingDiscontinuedOperationsDeferredRevenue
140000
apvo Other Noncash Operating Activities Discontinued Operations
OtherNoncashOperatingActivitiesDiscontinuedOperations
200000
apvo Deferred Payments Deferment Limit Period
DeferredPaymentsDefermentLimitPeriod
P45D
CY2019Q2 apvo Reduction In Research And Development Expense
ReductionInResearchAndDevelopmentExpense
100000
apvo Reduction In Research And Development Expense
ReductionInResearchAndDevelopmentExpense
500000
CY2020Q2 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
5600000
CY2019Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
12500000
apvo Cash Equivalents Maturity Period
CashEquivalentsMaturityPeriod
P90D
CY2020Q2 us-gaap Cash
Cash
2025000
CY2019Q4 us-gaap Cash
Cash
4954000
CY2020Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
5574000
CY2019Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
7494000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10154000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19946000
CY2020Q2 apvo Unamortized Loan Initiation Fees
UnamortizedLoanInitiationFees
100000
CY2020Q2 apvo Loss On Debt Extinguishment
LossOnDebtExtinguishment
2100000
apvo Operating Lease Property Number Of Lab Equipment
OperatingLeasePropertyNumberOfLabEquipment
1
apvo Operating Lease Property Number Of Copiers
OperatingLeasePropertyNumberOfCopiers
4
CY2020Q2 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
0
us-gaap Operating Lease Cost
OperatingLeaseCost
790000
CY2019Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
399000
us-gaap Operating Lease Cost
OperatingLeaseCost
734000
CY2020Q2 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
2000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
3000
CY2019Q2 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
2000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
3000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
1000
CY2020Q2 us-gaap Lease Cost
LeaseCost
397000
us-gaap Lease Cost
LeaseCost
793000
CY2019Q2 us-gaap Lease Cost
LeaseCost
401000
us-gaap Lease Cost
LeaseCost
738000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3416000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4692000
us-gaap Operating Lease Payments
OperatingLeasePayments
788000
us-gaap Operating Lease Payments
OperatingLeasePayments
868000
CY2020Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y9M18D
CY2020Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1454
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
a reverse split of Aptevo’s common stock at a ratio ranging from 1-for-2 to 1-for-20, inclusive, with the effectiveness of one of such amendments and the abandonment of the other amendments, or the abandonment of all amendments, to be determined by the Board in its sole discretion following the Special Meeting. The specific 1-for-14 reverse split ratio was subsequently approved by the Board on March 23, 2020. On March 26, 2020, the Company filed a Certificate of Amendment of Amended and Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to effect a 1-for-14 reverse stock split of the Company’s outstanding common stock
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
301000
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
401000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
714000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
995000
CY2019Q1 apvo Pre Funded Warrants And Rights Outstanding Term
PreFundedWarrantsAndRightsOutstandingTerm
P10Y
CY2019Q1 apvo Prefunded Warrant Expiration Date
PrefundedWarrantExpirationDate
2029-03-11
CY2020Q2 us-gaap Conversion Of Stock Description
ConversionOfStockDescription
On June 29, 2020, Aptevo commenced a voluntary employee and directors stock option exchange program (the “Exchange Program”) to permit the Company’s eligible employees, directors and certain consultants to exchange some or all of their eligible outstanding options (“Original Options”) to purchase the Company’s common stock with an exercise price greater than or equal to $21.00 per share

Files In Submission

Name View Source Status
0001564590-20-040295-index-headers.html Edgar Link pending
0001564590-20-040295-index.html Edgar Link pending
0001564590-20-040295.txt Edgar Link pending
0001564590-20-040295-xbrl.zip Edgar Link pending
apvo-10q_20200630.htm Edgar Link pending
apvo-20200630.xml Edgar Link completed
apvo-20200630.xsd Edgar Link pending
apvo-20200630_cal.xml Edgar Link unprocessable
apvo-20200630_def.xml Edgar Link unprocessable
apvo-20200630_lab.xml Edgar Link unprocessable
apvo-20200630_pre.xml Edgar Link unprocessable
apvo-ex311_8.htm Edgar Link pending
apvo-ex312_7.htm Edgar Link pending
apvo-ex321_9.htm Edgar Link pending
apvo-ex322_6.htm Edgar Link pending
exhibit10_1.htm Edgar Link pending
exhibit10_2.htm Edgar Link pending
exhibit10_3.htm Edgar Link pending
exhibit10_4.htm Edgar Link pending
exhibit10_5.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g883272dsp12.jpg Edgar Link pending
g883272dsp143a.jpg Edgar Link pending
g883272dsp143b.jpg Edgar Link pending
g883272dsp143c.jpg Edgar Link pending
g883272dsp146.jpg Edgar Link pending
g883272page040a.jpg Edgar Link pending
g883272page040b.jpg Edgar Link pending
g883272page111.jpg Edgar Link pending
g883272page112a.jpg Edgar Link pending
g883272page166.jpg Edgar Link pending
g883272page167.jpg Edgar Link pending
g883272page168.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending